Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Cabozantinib, marketed as Cabometyx TM, has received approval from both the FDA and EMA for the treatment of specific types of thyroid cancer. With these approvals, cabozantinib serves as a therapeutic option for both differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC) (1, 2, 3). Cabozantinib has been approved in the second-line setting for patients with RAI-R DTC who have progressed following up to two prior vascular endothelial growth factor receptor (VEGFR) targeted therapies (3…